<DOC>
	<DOCNO>NCT00536692</DOCNO>
	<brief_summary>This open-label study evaluate safety tolerability topical ocular mecamylamine give twice day patient diabetic macular edema ( DME ) . Patients treat 12 week .</brief_summary>
	<brief_title>Topical Ocular Mecamylamine Diabetic Macular Edema ( DME )</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Mecamylamine</mesh_term>
	<criteria>macular edema due diabetic retinopathy vision loss ocular disease intraocular surgery within 3 month intraocular antiVEGF steroid within 3 month HbA1c &gt; 12</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>macular edema</keyword>
	<keyword>DME</keyword>
	<keyword>diabetic</keyword>
	<keyword>mecamylamine</keyword>
	<keyword>Comentis</keyword>
</DOC>